包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Ledipasvir (GS-5885) hydrochloride is an inhibitor of thehepatitis C virus NS5A, withEC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also aSARS-CoV3CLproinhibitor with anIC50of 1.62 μM[3]. |
IC50& Target | EC50: 34 pM (GT1a), 4 pM (GT1b)[1] |
体外研究 (In Vitro) | Ledipasvir hydrochloride has GT1a and 1b EC50values of 31 and 4 pM, respectively, and protein-adjusted EC50values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC50of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir hydrochloride is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay[1]. Ledipasvir hydrochloride exhibits an EC50value of 141 nM against the JFH/3a-NS5A replicon[2]. |
体内研究 (In Vivo) | Ledipasvir hydrochloride is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir hydrochloride is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 hr, dog 2.63 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume[1]. |
Clinical Trial | |
分子量 | 925.46 |
Formula | C49H55ClF2N8O6 |
中文名称 | 盐酸雷迪帕韦;盐酸来地帕韦 |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |